Brief: Theranexus H1 Net Operating Loss Widens To 4.6 Million Euros

Thx Pharma SA

30/09/2021 17:27

Sept 30 (Reuters) - Theranexus SA  ALTHX.PA :
    * H1 NET LOSSES WERE -€3,723 K , COMPARED WITH -€2,870 K IN
THE
FIRST HALF OF 2020
    * TOTAL AVAILABLE FUNDS ON 30 JUNE 2021 STOOD AT €13.5 M,
COMPARED
WITH €11.2 M ON 31 DECEMBER 2020
    * COMPANY'S CASH POSITION IS RELATIVELY STABLE AND PROVIDES
FINANCIAL VISIBILITY FOR THE NEXT 18 MONTHS IN ACCORDANCE WITH
ITS SET TARGETS
    * DRUG CANDIDATE BBDF 101 FOR BATTEN DISEASE: CLINICAL
PROGRAM
WILL START BY THE END OF 2021 WITH PHASE I/II. PHASE III WILL
START AFTER CONSULTING WITH THE FDA IN THE SECOND HALF OF 2022
    * H1 NET OPERATING LOSS EUR 4.6 MILLION VERSUS LOSS EUR 3.4
MILLION YEAR AGO

Source text for Eikon:  ID:nNDL6nBFWf 
Further company coverage:  ALTHX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))